JP2001521382A5 - - Google Patents

Download PDF

Info

Publication number
JP2001521382A5
JP2001521382A5 JP1998542992A JP54299298A JP2001521382A5 JP 2001521382 A5 JP2001521382 A5 JP 2001521382A5 JP 1998542992 A JP1998542992 A JP 1998542992A JP 54299298 A JP54299298 A JP 54299298A JP 2001521382 A5 JP2001521382 A5 JP 2001521382A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1998542992A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001521382A (ja
Filing date
Publication date
Priority claimed from US08/872,855 external-priority patent/US6121045A/en
Application filed filed Critical
Priority claimed from PCT/US1998/006775 external-priority patent/WO1998045434A1/en
Publication of JP2001521382A publication Critical patent/JP2001521382A/ja
Publication of JP2001521382A5 publication Critical patent/JP2001521382A5/ja
Pending legal-status Critical Current

Links

JP54299298A 1997-04-04 1998-04-06 新規なヒトデルタ3組成物ならびにそれらの治療および診断への使用方法 Pending JP2001521382A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83263397A 1997-04-04 1997-04-04
US08/832,633 1997-04-04
US08/872,855 US6121045A (en) 1997-04-04 1997-06-11 Human Delta3 nucleic acid molecules
US08/872,855 1997-06-11
PCT/US1998/006775 WO1998045434A1 (en) 1997-04-04 1998-04-06 Novel human delta3 compositions and therapeutic and diagnostic uses therefor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009233349A Division JP2010004892A (ja) 1997-04-04 2009-10-07 新規なヒトデルタ3組成物ならびにそれらの治療および診断への使用方法

Publications (2)

Publication Number Publication Date
JP2001521382A JP2001521382A (ja) 2001-11-06
JP2001521382A5 true JP2001521382A5 (OSRAM) 2005-11-24

Family

ID=27125549

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54299298A Pending JP2001521382A (ja) 1997-04-04 1998-04-06 新規なヒトデルタ3組成物ならびにそれらの治療および診断への使用方法

Country Status (8)

Country Link
EP (1) EP0972041B2 (OSRAM)
JP (1) JP2001521382A (OSRAM)
AT (1) ATE342358T1 (OSRAM)
AU (1) AU6952498A (OSRAM)
CA (1) CA2285020A1 (OSRAM)
DE (1) DE69836131T3 (OSRAM)
ES (1) ES2275304T3 (OSRAM)
WO (1) WO1998045434A1 (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU723939B2 (en) 1995-06-28 2000-09-07 Imperial Cancer Research Technology Ltd Nucleotide and protein sequences of vertebrate delta genes and methods based thereon
US5780300A (en) * 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
WO1998051799A1 (en) * 1997-05-14 1998-11-19 Asahi Kasei Kogyo Kabushiki Kaisha Novel differentiation inhibitor
WO2000006726A2 (en) * 1998-07-27 2000-02-10 Amgen Inc. Delta-related polypeptides
US6703221B1 (en) 1999-08-19 2004-03-09 Chiron Corporation Notch receptor ligands and uses thereof
AU6913100A (en) * 1999-08-19 2001-03-13 Chiron Corporation Notch receptor ligands and uses thereof
GB9927328D0 (en) 1999-11-18 2000-01-12 Lorantis Ltd Immunotherapy
GB9927331D0 (en) 1999-11-18 2000-01-12 Fluorescience Ltd Assay for measuring enzyme activity in vivo
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
WO2003018799A2 (en) * 2001-08-22 2003-03-06 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
JP2003245084A (ja) 2001-12-20 2003-09-02 Morinaga Milk Ind Co Ltd 脳梁又は精子の形成不全の診断及び治療に有用な新規遺伝子、並びにその用途
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
US7906116B2 (en) 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
EP2511298B1 (en) 2005-10-31 2019-01-16 Oncomed Pharmaceuticals, Inc. Compositions and Methods for Treating Cancer based on human FZD receptors
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
AR061246A1 (es) 2006-06-06 2008-08-13 Genentech Inc Anticuerpos anti- dill4 y metodos que los usan
HUE028379T2 (en) 2006-09-29 2016-12-28 Oncomed Pharm Inc Preparations and procedures for the diagnosis and treatment of cancer
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
TWI506037B (zh) 2008-09-26 2015-11-01 Oncomed Pharm Inc 捲曲結合劑類及彼等之用途
WO2010054007A1 (en) 2008-11-07 2010-05-14 Fabrus Llc Combinatorial antibody libraries and uses thereof
US8883145B2 (en) 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt拮抗劑及治療和篩選方法
EP3907242A1 (en) 2010-01-29 2021-11-10 Chugai Seiyaku Kabushiki Kaisha Anti-dll3 antibody
WO2011123785A2 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
SI3485903T1 (sl) 2011-09-23 2023-02-28 Mereo Biopharma 5, Inc. Sredstva, ki vežejo VEGF/DLL4, in njihove uporabe
EP2911691B1 (en) 2012-10-23 2018-10-10 OncoMed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
JP2016510411A (ja) 2013-02-04 2016-04-07 オンコメッド ファーマシューティカルズ インコーポレイテッド Wnt経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US20160176962A1 (en) 2014-10-31 2016-06-23 Oncomed Pharmaceuticals, Inc. Combination Therapy For Treatment Of Disease
ES2968074T3 (es) 2015-09-23 2024-05-07 Mereo Biopharma 5 Inc Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino
EP3732195A4 (en) 2017-12-28 2022-02-09 Chugai Seiyaku Kabushiki Kaisha CYTOTOXICITY-INDUCING THERAPEUTIC

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101728A (en) 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
AU723939B2 (en) * 1995-06-28 2000-09-07 Imperial Cancer Research Technology Ltd Nucleotide and protein sequences of vertebrate delta genes and methods based thereon
ATE319827T1 (de) * 1995-11-17 2006-03-15 Asahi Chemical Ind Polypeptid, das die differenzierung unterdrueckt

Similar Documents

Publication Publication Date Title
JP2000510751A5 (OSRAM)
JP2000509912A5 (OSRAM)
JP2000509635A5 (OSRAM)
JP2000507042A5 (OSRAM)
JP2000509942A5 (OSRAM)
JP2000509637A5 (OSRAM)
JP2000509587A5 (OSRAM)
JP2000507369A5 (OSRAM)
JP2000507433A5 (OSRAM)
JP2000508866A5 (OSRAM)
JP2000510793A5 (OSRAM)
JP2001511733A5 (OSRAM)
JP2000508841A5 (OSRAM)
JP2000508680A5 (OSRAM)
JP2000509853A5 (OSRAM)
JP2000509755A5 (OSRAM)
JP2000510969A5 (OSRAM)
JP2000510247A5 (OSRAM)
JP2002510303A5 (OSRAM)
JP2000508102A5 (OSRAM)
JP2000508836A5 (OSRAM)
JP2001512521A5 (OSRAM)
JP2000509520A5 (OSRAM)
JP2000507434A5 (OSRAM)
JP2000508880A5 (OSRAM)